Tseng Chien-Wen, Lin Grace A, Davis James, Taira Deborah A, Yazdany Jinoos, He Qimei, Chen Randi, Imamura Allison, Dudley R Adams
Department of Family Medicine and Community Health, University of Hawaii John A. Burns School of Medicine, 677 Ala Moana Blvd, Ste. 815, Honolulu, HI, 96813, USA.
Pacific Health Research and Education Institute, Honolulu, USA.
BMC Health Serv Res. 2016 Sep 21;16(1):499. doi: 10.1186/s12913-016-1752-4.
Providers wish to help patients with prescription costs but often lack drug cost information. We examined whether giving providers formulary and drug cost information was associated with changes in their diabetes patients' drug costs and use. We conducted a longitudinal non-randomized evaluation of the web-based Prescribing Guide ( www.PrescribingGuide.com ), a free resource available to Hawaii's providers since 2006, which summarizes the formularies and copayments of six health plans for drugs to treat 16 common health conditions. All adult primary care physicians in Hawaii were offered the Prescribing Guide, and providers who enrolled received a link to the website and regular hardcopy updates.
We analyzed prescription claims from a large health plan in Hawaii for 5,883 members with diabetes from 2007 (baseline) to 2009 (follow-up). Patients were linked to 299 "main prescribing" providers, who on average, accounted for >88 % of patients' prescriptions and drug costs. We compared changes in drug costs and use for "study" patients whose main provider enrolled to receive the Prescribing Guide, versus "control" patients whose main provider did not enroll to receive the Prescribing Guide.
In multivariate analyses controlling for provider specialty and clustering of patients by providers, both patient groups experienced similar increases in number of prescriptions (+3.2 vs. +2.7 increase, p = 0.24), and days supply of medications (+141 vs. +129 increase, p = 0.40) averaged across all drugs. Total and out-of-pocket drug costs also increased for both control and study patients. However, control patients showed higher increases in yearly total drug costs of $208 per patient (+$792 vs. +$584 increase, p = 0.02) and in 30-day supply costs (+$9.40 vs. +$6.08 increase, p = 0.03). Both groups experienced similar changes in yearly out-of-pocket costs (+$41 vs + $31 increase, p = 0.36) and per 30-day supply (-$0.23 vs. -$0.19 decrease, p = 0.996).
Giving formulary and drug cost information to providers was associated with lower increases in total drug costs but not with lower out-of-pocket costs or greater medication use. Insurers and health information technology businesses should continue to increase providers' access to formulary and drug cost information at the point of care.
医疗服务提供者希望帮助患者解决处方药费用问题,但往往缺乏药品成本信息。我们研究了向医疗服务提供者提供药品处方集和药品成本信息是否与他们糖尿病患者的药品成本和使用情况的变化有关。我们对基于网络的《处方指南》(www.PrescribingGuide.com)进行了一项纵向非随机评估,该指南自2006年起可供夏威夷的医疗服务提供者免费使用,它总结了六种健康计划针对治疗16种常见健康状况的药物的处方集和自付费用。夏威夷所有的成年初级保健医生都收到了《处方指南》的推荐,注册的医疗服务提供者会收到该网站的链接以及定期的纸质更新资料。
我们分析了夏威夷一个大型健康计划中5883名糖尿病患者在2007年(基线)至2009年(随访)期间的处方报销记录。患者与299名“主要开方”医疗服务提供者相关联,这些提供者平均开出了患者超过88%的处方和承担了超过88%的药品费用。我们比较了“研究”组患者(其主要医疗服务提供者注册以接收《处方指南》)与“对照”组患者(其主要医疗服务提供者未注册以接收《处方指南》)在药品成本和使用情况上的变化。
在控制了医疗服务提供者专业以及患者按提供者聚类的多变量分析中,两组患者在所有药物的平均处方数量增加方面相似(分别增加3.2张与2.7张,p = 0.24),以及药品供应天数增加方面相似(分别增加141天与129天,p = 0.40)。对照组和研究组患者的总药品成本和自付药品成本也都有所增加。然而,对照组患者的年度总药品成本增加更高,每位患者增加208美元(分别增加792美元与584美元,p = 0.02),30天药品供应成本增加更高(分别增加9.40美元与6.08美元,p = 0.03)。两组患者在年度自付费用增加方面相似(分别增加41美元与31美元,p = 0.36),每30天药品供应的自付费用变化相似(分别减少0.23美元与0.19美元,p = 0.996)。
向医疗服务提供者提供处方集和药品成本信息与总药品成本较低的增加相关,但与较低的自付费用或更多的药物使用无关。保险公司和健康信息技术企业应继续在医疗服务点增加医疗服务提供者获取处方集和药品成本信息。